Creating an aggregate outcome index: Cost-effectiveness analysis of substance abuse treatment

Journal of Behavioral Health Services and Research

Volumn 31, Issue 3, 2004, Pages 229-241

  Jofre Bonet, Mireia ^b   Sindelar, Jody L ^a  

^a YALE UNIVERSITY   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL ABUSE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; EMPLOYMENT; FAMILY; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE POLICY; HUMAN; HUMAN RELATION; MENTAL DISEASE; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; ADDICTION; COST BENEFIT ANALYSIS; INFORMATION PROCESSING; OUTCOME ASSESSMENT; STATISTICS; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DATA COLLECTION; GREAT BRITAIN; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PHILADELPHIA; SUBSTANCE-RELATED DISORDERS;

EID: 4043161487     PISSN: 10943412     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075484-200407000-00001     Document Type: Article

References (26)

1. Alterman AI, O'Brien CP, McLellan AT, et al. Effectiveness and cost of inpatient versus day hospital cocaine rehabilitation. Journal of Nervous and Mental Disease. 1994;182(3):157-163.
2. Barnett P, Swindle R. Cost-effectiveness of inpatient substance abuse treatment. Health Services Research. 1997;32(5):615-629.
3. Cartwright W. Cost benefit and cost-effectiveness analysis of drug abuse treatment services. Evaluation Review. 1998;22(5):609-636.
4. Kraft MK, Rothbard AB, Hadley TR, et al. Are supplementary services provided during methadone maintenance really cost effective? American Journal of Psychiatry. 1997;154(9):1214-1219.
5. Shephard D, Larson MJ, Hoffman N. Cost-effectiveness of substance abuse services. Addictive Disorders. 1999;22(2):385-399.
6. McLellan AT, Weisner C. Achieving the public health and safety potential of substance abuse treatment. In: Bikle W, De Grandpre RJ, eds. Drug Policy and Human Nature: Psychological Perspectives on the Prevention, Management and Treatment of Illicit Drug Abuse. New York: Plenum Press; 1996:127-154.
7. Sindelar JL, Jofre-Bonet M, French M, McLellan AT. Cost effectiveness analysis: Paradoxes of multiple outcomes. Drug and Alcohol Dependence. 2004;73(1):41-50.
8. Carroll KM. Methodological issues and problems in assessment of substance use. Psychological Assessment. 1995;7:349-358.
9. McLellan AT, O'Brien CP, Luborsky L, et al. Are the addiction-related problems of substance abusers really related? Journal of Nervous and Mental Disease. 1981;169(4):232-239.
10. McLellan AT, Luborsky L, O'Brien CP, et al. An improved evaluation instrument for substance abuse patients: the Addiction Severity Index. Journal of Nervous and Mental Disease. 1980;168:26-33, 38.
11. McLellan AT, Luborsky L, Erdlen F, et al. The Addiction Severity Index: A diagnostic/evaluative instrument for substance abuse clients. In: Gottheil E, McLellan AT, Druley KD, eds. Substance Abuse and Psychiatric Illness. New York: Pergamon Press; 1980.
12. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programs. 2nd ed. Oxford University Press; 1997.
13. Bury D, Shepard D. Developing a utility index for substance abuse: theory and application. Paper presented at: International Health Economics Association Conference; June 6, 1999; England.
14. Rosenheck R, Cramer J, Xu W, et al. Multiple outcome assessment in a study of the cost-effectiveness of Clozapine in the treatment of refractory schizophrenia. Health Services Research. 1998;33(5, I):1237-1261.
15. Kleiman R. Preferences for Outpatient Mental Health Treatment [doctoral dissertation]. Baltimore, Md: John Hopkins Press; 1995.
16. Kenkel D. On valuing morbidity, cost-effectiveness analysis, and being rude. Journal of Health Economics. 1997;16:749-757.
17. Reuter P. Are calculations of the economic costs of drug abuse either possible or useful? Addiction. 1999;94(5):635-638.
18. French MT, Mauskopf JE, Teague JL, et al. Estimating the dollar value of health outcomes from drug-abuse interventions. Medical Care. 1996;34:890-910.
19. French MT, McGeary KA. Estimating the economic cost of substance abuse treatment. Health Economics. 1997;6:539-544.
20. French MT, Salome HJ, Krupski A, et al. Benefit-cost analysis of residential and outpatient addiction treatment in the state of Washington. Evaluation Review. 2000;24(6):609-634.
21. French MT, Salome HIJ, Sindelar JL, et al. Benefit cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI. Health Services Research. 2002;37(2):433-455.
22. Sindelar JL, Manning WG. Cost-benefit and cost-benefit analysis: issues in the evaluation of the treatment of illicit drug abuse. In: Egertson J, Fox D, Leshner A, eds. Treating Drug Abusers Effectively. Oxford: Blackwell; 1997:187-222.
23. Zarkin G, French M, Anderson D. A conceptual framework for the economic evaluation of substance abuse interventions. Evaluation and Program Planning. 1994;17(4):409-418.
24. McLellan AT, Hagan TA, Levine M, et al. Does clinical case management improve outpatient addiction treatment. Drug Alcohol Dependence. 1999;55(1/2):91-103.
25. McLellan AT, Hagan TA, Meyers K, et al. Supplemental social services improve outcomes in public addiction treatment. Addiction. 1998;93(10):1489- 1499.
26. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.